An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry
Background: In 2013, eribulin was reimbursed under a coverage with evidence development (CED) as third or later chemotherapy line for advanced breast cancer (ABC) patients in the Netherlands because of uncertain cost effectiveness. In 2016, the final decision of reimbursing eribulin was taken without considering the evidence collected during CED research. We analysed the cost effectiveness of eribulin versus non-eribulin chemotherapy, using real-world data. Methods: A three health states (progression-free, progressed disease, dead) partitioned survival model was developed. The SOuth East Nethe... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Dataset |
Erscheinungsdatum: | 2020 |
Schlagwörter: | Medicine / Pharmacology / Biotechnology / Sociology / Cancer / Science Policy / Plant Biology / QALY / chemotherapy line / budget impact / CED / SOuth East Netherlands Advanced BRE. / health state utility values / EVPI / SONABRE / ICER / breast cancer treatment / non-eribulin chemotherapy / breast cancer registry Background / Incremental cost-effectiveness ratio / ABC / cost effectiveness |
Sprache: | unknown |
Permalink: | https://search.fid-benelux.de/Record/base-27594264 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.6084/m9.figshare.12493685.v3 |